1. Validation of a novel direct method to determine reduced adherence to atorvastatin therapy, European Heart Journal Cardiovascular Pharmacotherapy 2024
  2. The atorvastatin metabolite pattern in muscle tissue and blood plasma is associated with statin muscle side effects in patients with coronary heart disease; An exploratory case-control study, Atherosclerosis Plus 2024
  3. A multi-component intervention increased access to smoking cessation treatment after hospitalization for atherosclerotic cardiovascular disease. A randomized trial.European Heart Journal Open, 2024
  4. Treatment patterns and adherence to lipid-lowering drugs during eight-year follow-up after a coronary heart disease event. Atherosclerosis, 2024
  5. Statin adherence in coronary outpatients: the relationship between a novel direct method and pharmacy registry data. Poster presentasjon av Jonas Pivoriunas mfl. (NORCOR gruppen). ESC Preventive Cardiology Annual Congress, 25 April –  27 April 2024 Aten – Hellas.
  6. Adipose tissue insulin resistance in South Asian and Nordic women after gestational diabetes mellitus. Metabolites 2024
  7. 2023 ESC guidelines for the mamagement of cardiovascular disease in patients with diabetes. Hjerteforum 2024 (s. 29)
  8. Statin adherence in coronary outpatients: a novel direct method compared with pharmacy registry data. European Journal of Preventive Cardiology 2024 (Supplement)
  9. Cognitive behavioural therapy for insomnia (CBT-I) in patients with coronary heart disease: a protocol for a randomized controlled trial with six months follow-up. European Journal of Preventive Cardiology 2024 (protokoll)
  10. The effect of atorvastatin on mevalonate levels in blood plasma in patients with coronary heart disease and muscle side effects. European Journal of Preventive Cardiology 2024 (supplement)
  11. 2023 ESC guidelines for the mamagement of cardiovascular disease in patients with diabetes. Hjerteforum N° 2/ 2024/ vol 37 (s. 27-31)
  12. N-terminal pro-B-type natriuretic peptide levels vary by ethnicity and are associated with insulin sensitivity after gestational diabetes mellitus. Cardiovascular Diabetology 2024
  13. Association of normal body mass index and weight loss with long-term major cardiovascular events after PCI for myocardial infarction. Scandinavian Cardiovascular Journal 2024
  14. Statin discontinuation: How can we improve on the multiple pathways that contribute to suboptimal statin adherence? Polish Heart Journal (Kardiologia Polska) 2024 (Brev til redaktøren)
  15. High discontinuation rate of statins among PCSK9i users: A nationwide study from 2015-2023. Ingrid Engebretsen, Kristina Malene Ødegaard, Sigrun Halvorsen, Christoffer Bugge, Ivar Sønbø Kristiansen, Henrik Støvring, John Munkhaugen. Oral abstract presentation at ESC European Society of Cardiology Congress 2024, London.
  16. Mevalonate in blood and muscle: Response to atorvastatin treatment and the relationship to statin intolerance in patients with coronary heart disease. Clinical and Translational Science 2024
  17. Estimation of individual lifetime cardiovascular disease risk and treatment benefit in patients with established atherosclerotic cardiovascular disease: the updated SMART-REACH2 model. European Heart Journal, Supplement. 2024
  18. High discontinuation rate of statins among PCSK9i users: a nationwide study from 2015-2023. European Heart Journal, Supplement. 2024
  19. Forhåndssamtaler om siste livsfase. Tidsskrift for Den norske legeforening 2024
  20. Treatment with PCSK9 monoclonal antibodies is associated with discontinuation of oral lipid lowering therapy. European Heart Journal – Quality of Care and Clinical Outcomes, 2024
  21. Inntrykk fra ESC Preventive Cardiology Congress, Hjerteforum N° 3/ 2024/ vol 37 (s. 3; 85-75)